Patients receiving sitagliptin with metformin and glimepiride had significant improvements in A1C and FPG compared to patients receiving placebo with metformin and glimepiride (Table 11), with mean reductions from baseline relative to placebo in A1C of -0.9% and in FPG of -21 mg/dL
Book your telehealth consultation to explore the most suitable medication for you
Fewer Disease Flares With GLP-1 Therapy In a retrospective study led by Shreya Sakthivel, Chief Resident of Internal Medicine at Anne Arundel Medical Center, investigators found that RA patients receiving disease-modifying antirheumatic drugs (DMARDs) who also took GLP-1 receptor agonists or SGLT2 inhibitors experienced fewer disease flares than those on DMARDs alone
L-Carnitine plays a role in energy metabolism and production
They tended to be older and have a higher body mass index, higher rates of bariatric surgery and chronic hypertension, and present earlier for prenatal care
Researchers reported that reproductive improvements appeared earlier than expected in participants who lost at least 10% of their body weight during treatment